Precision medicine for acute myeloid leukemia

Catherine Lai, Judith E. Karp, Christopher Hourigan

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The goal of precision medicine is to personalize therapy based on individual patient variation, to correctly select the right treatment, for the right patient, at the right time. Acute myeloid leukemia (AML) is a heterogeneous collection of myeloid malignancies with diverse genetic etiology and the potential for intra-patient clonal evolution over time. We discuss here how the precision medicine paradigm might be applied to the care of AML patients by focusing on the potential roles of targeting therapy by patient-specific somatic mutations and aberrant pathways, ex-vivo drug sensitivity and resistance testing, high sensitivity measurements of residual disease burden and biology along with potential clinical trial and regulatory constraints.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalExpert review of hematology
Issue number1
StatePublished - Jan 1 2016


  • AML
  • Leukemia
  • Measurable residual disease
  • Minimal residual disease
  • Mrd
  • Personalized medicine
  • Precision medicine
  • Screening
  • Sensitivity

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Precision medicine for acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this